Psoriasis is a chronic inflammatory skin condition affecting more than 125 million individuals worldwide.1 It is associated with mortality and multimorbidity. The introduction of a plethora of biologic drugs has transformed patient outcomes such that skin clearance is now a realistic treatment goal. Psoriasis biologic drugs target tumour necrosis factor α (etanercept, infliximab, adalimumab, and certolizumab), the p40 subunit of interleukin (IL)-12 and IL-23 (ustekinumab), IL-17 (secukinumab [IL-17A], ixekizumab [IL-17A], and brodalumab [IL-17RA]), and the p19 subunit of IL-23 (IL-23p19; guselkumab, tildrakizumab, and risankizumab).
Original Article: [Comment] Psoriasis biologics: a new era of choice